Profound Medical Signs Agreement With Telix Pharmaceuticals To Educate Urologists, Radiologists, Nuclear Medicine Physicians, Prostate Cancer Centers Over Roles Of Telix’s Advanced Prostate-Specific Membrane Antigen
Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets innovative interventional MRI ("iMRI") procedures,
Profound Medical and Telix partnered to teach doctors about a new prostate cancer tool. When companies work together on education, it often means they believe in the technology's future.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.